Data Transparency and Drug Safety Act of 2022

Bill: 117-hr-6431
Sponsor: full_name: Rep. Schrier, Kim [D-WA-8]
Introduced: 2022-01-19
Policy area: Health
Latest action: action_date: 2022-01-20
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-01-19
action_desc: Introduced in House
text: <p><strong>Data Transparency and Drug Safety Act of 2022</strong></p> <p>This bill makes it a prohibited act under the Federal Food, Drug, and Cosmetic Act to destroy or falsify certain records pertaining to drugs regulated by the Food and Drug Administration (FDA). </p> <p>Specifically, the bill prohibits falsifying, destroying, omitting. or removing records or information that (1) must be produced during the development or manufacture of a drug, (2) must be produced in an application for FDA approval for a drug or maintained after a drug is approved, or (3) is subject to FDA inspection. </p> <p>A person (entity or individual) that violates this provision shall be subject to civil monetary penalties. The bill also provides for additional monetary penalties in instances where the violation is not sufficiently remedied after the responsible person has received written notice from the FDA of the violation. </p>

tv_txt: I 117th CONGRESS 2d Session H. R. 6431 IN THE HOUSE OF REPRESENTATIVES January 19, 2022 Ms. Schrier (for herself and Mr. Joyce of Pennsylvania ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to prohibit the alteration, falsification, fabrication, destruction, omission, or removal of records or certain information required to be produced or maintained for a drug, and for other purposes.

1. Short title This Act may be cited as the Data Transparency and Drug Safety Act of 2022 . 2. Enhanced penalties for false information and records destruction (a) Prohibition of false information and record destruction Section 301 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 331 ) is amended by adding at the end the following: (fff) The alteration, falsification, fabrication, destruction, omission, or removal of the whole or any part of records or information that is— (1) required under this Act— (A) to be produced during the development or manufacture of a drug; or (B) to be produced or maintained by the sponsor of an application for the approval of a drug under section 505 or the holder of an approved application for a drug under section 505; or (2) subject to inspection under this Act by the Secretary. . (b) Penalties Section 303 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333 ) is amended by adding at the end the following: (h) Notwithstanding subsection (a), any person who violates section 301(fff) shall be subject to— (1) a civil monetary penalty not to exceed— (A) $1,000,000 per violation; and (B) $10,000,000 for all violations (excluding those described in paragraph (2)) adjudicated in a single proceeding; and (2) in the case of a violation that continues after the Secretary provides written notice to such person, if such person does not sufficiently remedy the violation including by producing corrected records or information, additional civil penalties not to exceed— (A) $1,000,000 for the first 30-day period (or any portion thereof) following such notice during which such person continues to be in violation; (B) for each such 30-day period thereafter, the amount that is double the amount actually imposed for the preceding 30-day period, not to exceed $2,000,000 for any 30-day period; and (C) $20,000,000 for all violations described in this paragraph adjudicated in a single proceeding. .